Published in J Clin Invest on November 01, 1985
N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study) | NCT00374088
Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest (1994) 4.28
Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest (2005) 4.14
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med (2007) 3.29
Tissue injury in inflammation. Oxidants, proteinases, and cationic proteins. J Clin Invest (1987) 2.93
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol (2010) 2.52
Nitric oxide, superoxide, and peroxynitrite in myocardial ischaemia-reperfusion injury and preconditioning. Br J Pharmacol (2003) 2.26
Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res (2009) 2.10
Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev (2014) 1.96
Remote ischaemic pre- and delayed postconditioning - similar degree of cardioprotection but distinct mechanisms. Exp Physiol (2012) 1.80
Blockade of self-reactive IgM significantly reduces injury in a murine model of acute myocardial infarction. Cardiovasc Res (2010) 1.78
Impaired perfusion after myocardial infarction is due to reperfusion-induced deltaPKC-mediated myocardial damage. Cardiovasc Res (2006) 1.70
Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest (1996) 1.65
Hypoxia-inducible factor 1 and cardiovascular disease. Annu Rev Physiol (2013) 1.52
Endotoxin pretreatment increases endogenous myocardial catalase activity and decreases ischemia-reperfusion injury of isolated rat hearts. Proc Natl Acad Sci U S A (1989) 1.50
Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest (1991) 1.48
Pathophysiology and pathogenesis of stunned myocardium. Depressed Ca2+ activation of contraction as a consequence of reperfusion-induced cellular calcium overload in ferret hearts. J Clin Invest (1987) 1.41
Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear. Proc Natl Acad Sci U S A (1990) 1.35
Mitochondrial oxidant stress triggers cell death in simulated ischemia-reperfusion. Biochim Biophys Acta (2010) 1.35
CMR of microvascular obstruction and hemorrhage in myocardial infarction. J Cardiovasc Magn Reson (2012) 1.33
History and use of del Nido cardioplegia solution at Boston Children's Hospital. J Extra Corpor Technol (2012) 1.30
Xanthine oxidase produces hydrogen peroxide which contributes to reperfusion injury of ischemic, isolated, perfused rat hearts. J Clin Invest (1988) 1.29
Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality? Heart (2000) 1.23
Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol (2012) 1.19
Effects of exogenous free radicals on electromechanical function and metabolism in isolated rabbit and guinea pig ventricle. Implications for ischemia and reperfusion injury. J Clin Invest (1989) 1.18
Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev (2002) 1.16
Remote postconditioning by humoral factors in effluent from ischemic preconditioned rat hearts is mediated via PI3K/Akt-dependent cell-survival signaling at reperfusion. Basic Res Cardiol (2010) 1.15
Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. Proc Natl Acad Sci U S A (2013) 1.12
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis (2009) 1.08
Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol (2016) 1.08
Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism. Anesthesiology (2010) 1.07
Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med (2007) 1.07
ROS-mediated PARP activity undermines mitochondrial function after permeability transition pore opening during myocardial ischemia-reperfusion. J Am Heart Assoc (2013) 1.06
Blockade of the natriuretic peptide receptor guanylyl cyclase-A inhibits NF-kappaB activation and alleviates myocardial ischemia/reperfusion injury. J Clin Invest (2001) 1.04
Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart. Am J Pathol (1998) 1.01
The pathophysiology of myocardial reperfusion: a pathologist's perspective. Heart (2006) 1.01
Protease-activated receptor 2 deficiency reduces cardiac ischemia/reperfusion injury. Arterioscler Thromb Vasc Biol (2010) 1.00
Prognostic value at 5 years of microvascular obstruction after acute myocardial infarction assessed by cardiovascular magnetic resonance. J Cardiovasc Magn Reson (2012) 1.00
Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction. J Clin Invest (2015) 1.00
In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One (2010) 0.99
Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am J Pathol (1990) 0.98
Serial changes in the T1 magnetic relaxation parameter after myocardial infarction in man. Br Heart J (1988) 0.97
AMPK-regulated and Akt-dependent enhancement of glucose uptake is essential in ischemic preconditioning-alleviated reperfusion injury. PLoS One (2013) 0.97
Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur J Pharmacol (2008) 0.96
Interrelationships between increased vascular permeability and acute neuronal damage following temperature-controlled brain ischemia in rats. Acta Neuropathol (1991) 0.96
Stromal derived factor 1α: a chemokine that delivers a two-pronged defence of the myocardium. Pharmacol Ther (2014) 0.95
Protective effects of M40403, a selective superoxide dismutase mimetic, in myocardial ischaemia and reperfusion injury in vivo. Br J Pharmacol (2002) 0.94
Study of antioxidative effects and anti-inflammatory effects in mice due to low-dose X-irradiation or radon inhalation. J Radiat Res (2013) 0.94
Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging (2016) 0.93
Reactive oxygen metabolites and the human myocardium. Br Heart J (1989) 0.92
Beneficial effects of N-acetylcysteine and cysteine in stunned myocardium in perfused rat heart. Br J Pharmacol (1991) 0.92
Bundled postconditioning therapies improve hemodynamics and neurologic recovery after 17 min of untreated cardiac arrest. Resuscitation (2014) 0.90
Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br J Pharmacol (2007) 0.90
Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts. J Clin Invest (1988) 0.90
Reperfusion-induced injury: a possible role for oxidant stress and its manipulation. Cardiovasc Drugs Ther (1991) 0.90
Antioxidant network expression abrogates oxidative posttranslational modifications in mice. Am J Physiol Heart Circ Physiol (2011) 0.89
Priming of polymorphonuclear neutrophils by atrial natriuretic peptide in vitro. J Clin Invest (1992) 0.89
Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia. Clinics (Sao Paulo) (2009) 0.89
Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury. Br J Clin Pharmacol (1989) 0.89
Ischaemic conditioning: pitfalls on the path to clinical translation. Br J Pharmacol (2015) 0.89
Nifedipine in acute myocardial infarction: an assessment of left ventricular function, infarct size, and infarct expansion. A double blind, randomised, placebo controlled trial. Br Heart J (1988) 0.89
Cardiovascular science: opportunities for translating research into improved care. J Clin Invest (2013) 0.88
Resveratrol, a polyphenol phytoalexin, protects cardiomyocytes against anoxia/reoxygenation injury via the TLR4/NF-κB signaling pathway. Int J Mol Med (2012) 0.88
The treatment of acute myocardial infarction: the Past, the Present, and the Future. Eur Heart J Acute Cardiovasc Care (2012) 0.87
Rho-kinase activation in leukocytes plays a pivotal role in myocardial ischemia/reperfusion injury. PLoS One (2014) 0.87
Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res (2009) 0.86
Pharmacological postconditioning with tanshinone IIA attenuates myocardial ischemia-reperfusion injury in rats by activating the phosphatidylinositol 3-kinase pathway. Exp Ther Med (2014) 0.86
Achyranthes bidentata polypeptides reduces oxidative stress and exerts protective effects against myocardial ischemic/reperfusion injury in rats. Int J Mol Sci (2013) 0.86
Selective β2-adrenoreceptor stimulation attenuates myocardial cell death and preserves cardiac function after ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol (2012) 0.86
Inflammatory response, neutrophil activation, and free radical production after acute myocardial infarction: effect of thrombolytic treatment. Br Heart J (1990) 0.85
Xanthine oxidase-derived hydrogen peroxide contributes to ischemia reperfusion-induced edema in gerbil brains. J Clin Invest (1988) 0.85
Ischemic conditioning: the challenge of protecting the diabetic heart. Cardiovasc Diagn Ther (2014) 0.85
Aldose reductase modulates cardiac glycogen synthase kinase-3β phosphorylation during ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2012) 0.85
Acidification asymmetrically affects voltage-dependent anion channel implicating the involvement of salt bridges. J Biol Chem (2014) 0.84
miR-19b attenuates H2O2-induced apoptosis in rat H9C2 cardiomyocytes via targeting PTEN. Oncotarget (2016) 0.84
Effect of HEMADO on Level of CK-MB and LDH Enzymes after Ischemia/Reperfusion Injury in Isolated Rat Heart. Bioimpacts (2012) 0.84
Myocardial ischemia, reperfusion, and infarction in chronically instrumented, intact, conscious, and unrestrained mice. Am J Physiol Regul Integr Comp Physiol (2012) 0.84
Intra-coronary administration of tacrolimus markedly attenuates infarct size and preserves heart function in porcine myocardial infarction. J Inflamm (Lond) (2012) 0.84
Reperfusion Injury: Basic Concepts and Protection Strategies. J Thromb Thrombolysis (1997) 0.84
Protection of the ischemic myocardium during the reperfusion: between hope and reality. Am J Cardiovasc Dis (2012) 0.83
On-pump inhibition of es-ENT1 nucleoside transporter and adenosine deaminase during aortic crossclamping entraps intracellular adenosine and protects against reperfusion injury: role of adenosine A1 receptor. J Thorac Cardiovasc Surg (2012) 0.83
Remote ischaemic conditioning: cardiac protection from afar. Anaesthesia (2015) 0.83
Basic study on active changes in biological function of mouse liver graft in cold storage after low-dose x-irradiation. J Clin Biochem Nutr (2009) 0.83
Innate immune response after acute myocardial infarction and pharmacomodulatory action of tacrolimus in reducing infarct size and preserving myocardial integrity. J Biomed Sci (2013) 0.83
Role of tumour necrosis factor-alpha and other cytokines in ischemia-reperfusion-induced injury in the heart. Exp Clin Cardiol (2005) 0.83
Depletion of PHD3 protects heart from ischemia/reperfusion injury by inhibiting cardiomyocyte apoptosis. J Mol Cell Cardiol (2015) 0.83
Endoplasmic reticulum stress response in spontaneously hypertensive rats is affected by myocardial ischemia reperfusion injury. Exp Ther Med (2014) 0.83
Ischemia, reperfusion, and the determinants of tissue injury. Cardiovasc Drugs Ther (1990) 0.83
Mitochondrial p38β and manganese superoxide dismutase interaction mediated by estrogen in cardiomyocytes. PLoS One (2014) 0.83
Cardioprotective and endothelial protective effects of [Ala-IL8]77 in a rabbit model of myocardial ischaemia and reperfusion. Br J Pharmacol (1991) 0.83
The Role of Mitochondrial Reactive Oxygen Species in Cardiovascular Injury and Protective Strategies. Oxid Med Cell Longev (2016) 0.83
Postconditioning with simvastatin decreases myocardial injury in rats following acute myocardial ischemia. Exp Ther Med (2015) 0.82
The acute inflammatory response to myocardial infarction: imaging with indium-111 labelled autologous neutrophils. Br Heart J (1987) 0.82
CaMKII-dependent phosphorylation of cardiac ryanodine receptors regulates cell death in cardiac ischemia/reperfusion injury. J Mol Cell Cardiol (2014) 0.82
Preserved coronary endothelial function by inhibition of delta protein kinase C in a porcine acute myocardial infarction model. Int J Cardiol (2008) 0.81
Imaging microvascular obstruction and its clinical significance following acute myocardial infarction. Heart Fail Rev (2006) 0.81
Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts. J Mol Cell Cardiol (2013) 0.81
Prevention of postoperative atrial fibrillation: novel and safe strategy based on the modulation of the antioxidant system. Front Physiol (2012) 0.81
Morphological consequences of early reperfusion following thrombotic or mechanical occlusion of the rat middle cerebral artery. Acta Neuropathol (1989) 0.81
The biology of oxygen radicals. Science (1978) 13.21
Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med (1985) 11.68
Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med (1980) 7.59
The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation (1977) 5.67
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest (1974) 4.42
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Superoxide radicals in feline intestinal ischemia. Gastroenterology (1981) 4.04
Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation (1983) 4.01
The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest (1979) 3.87
Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol (1960) 3.09
Cerebral ischemia. III. Vascular changes. Am J Pathol (1968) 2.67
Canine myocardial reperfusion injury. Its reduction by the combined administration of superoxide dismutase and catalase. Circ Res (1984) 2.44
Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol (1983) 2.37
Regulation of cellular volume. Physiol Rev (1977) 2.37
Myocardial alterations due to free-radical generation. Am J Physiol (1984) 2.20
EXPERIMENTAL ACUTE MYOCARDIAL INFARCTION; HISTOLOGIC AND HISTOCHEMICAL STUDIES OF EARLY MYOCARDIAL INFARCTS INDUCED BY TEMPORARY OR PERMANENT OCCLUSION OF A CORONARY ARTERY. Lab Invest (1964) 2.08
Lethal myocardial ischemic injury. Am J Pathol (1981) 2.05
Molecular oxygen: friend and foe. The role of the oxygen free radical system in the calcium paradox, the oxygen paradox and ischemia/reperfusion injury. J Mol Cell Cardiol (1984) 2.03
Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol (1984) 2.00
Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol (1985) 2.00
The oxygen paradox and the calcium paradox: two facets of the same problem? J Mol Cell Cardiol (1978) 1.95
Role of free radicals in catecholamine-induced cardiomyopathy. Can J Physiol Pharmacol (1982) 1.87
Effect of reperfusion late in the phase of reversible ischemic injury. Changes in cell volume, electrolytes, metabolites, and ultrastructure. Circ Res (1985) 1.83
An approach to free radicals in medicine and biology. Acta Physiol Scand Suppl (1980) 1.81
Superoxide dismutase plus catalase enhances the efficacy of hypothermic cardioplegia to protect the globally ischemic, reperfused heart. J Thorac Cardiovasc Surg (1982) 1.79
Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest (1972) 1.78
The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand Suppl (1980) 1.78
Reperfusion of the ischemic myocardium. J Mol Cell Cardiol (1977) 1.74
Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation (1980) 1.67
The role of lipid peroxidation in pathogenesis of ischemic damage and the antioxidant protection of the heart. Basic Res Cardiol (1983) 1.60
Deleterious effects due to hemorrhage after myocardial reperfusion. Am J Cardiol (1974) 1.51
Tissue osmolality, cell swelling, and reperfusion in acute regional myocardial ischemia in the isolated porcine heart. Circ Res (1981) 1.46
Prolonged derangements of canine myocardial purine metabolism after a brief coronary artery occlusion not associated with anatomic evidence of necrosis. Proc Natl Acad Sci U S A (1980) 1.37
Prolonged depletion of ATP and of the adenine nucleotide pool due to delayed resynthesis of adenine nucleotides following reversible myocardial ischemic injury in dogs. J Mol Cell Cardiol (1981) 1.37
Role of oxygen radicals in cardiac injury due to reoxygenation. J Mol Cell Cardiol (1984) 1.35
Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation (1984) 1.27
LOW INCIDENCE OF CORONARY THROMBOSIS IN MYOCARDIAL INFARCTION. A RESTUDY BY SERIAL BLOCK TECHNIQUE. Arch Pathol (1964) 1.21
Proton and free oxygen radical interaction with the calcium transport system of cardiac sarcoplasmic reticulum. J Mol Cell Cardiol (1981) 1.17
Hydrogen peroxide and hydroxyl radical mediation of activated leukocyte depression of cardiac sarcoplasmic reticulum. Participation of the cyclooxygenase pathway. Circ Res (1983) 1.14
Low calcium reperfusion of ischemic myocardium. J Mol Cell Cardiol (1983) 1.12
Effect of coronary reperfusion on myocardial hemorrhage and infarct healing. Am J Cardiol (1983) 1.11
The protective effect of hyperosmotic mannitol in myocardial ischemia and necrosis. Circulation (1976) 1.10
Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J Am Coll Cardiol (1983) 1.10
Functional improvement of jeopardized myocardium following intracoronary streptokinase infusion in acute myocardial infarction. J Clin Invest (1983) 1.05
Response of reperfusion-salvaged, stunned myocardium to inotropic stimulation. Am Heart J (1984) 1.03
The aggressive treatment of acute myocardial infarction. Circulation (1985) 0.96
Myocardial cell volume and coronary resistance during diminished coronary perfusion. Am J Physiol (1984) 0.96
The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation (1984) 0.96
Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion. Circulation (1985) 0.92
Hemorrhagic myocardial infarction after streptokinase treatment for acute coronary thrombosis. Arch Pathol Lab Med (1984) 0.88
Coronary reperfusion for the treatment of acute myocardial infarction: postischemic ventricular dysfunction. Cardiology (1983) 0.87
Effects of propranolol on myocardial infarct size with and without coronary artery reperfusion in the dog. Cardiovasc Res (1981) 0.86
Early membrane damage during coronary reperfusion in dogs. Detection by radiolabeled anticardiac myosin (Fab')2. J Clin Invest (1983) 0.85
Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (2). N Engl J Med (1984) 0.84
A flow- and time-dependent index of ischemic injury after experimental coronary occlusion and reperfusion. Proc Natl Acad Sci U S A (1983) 0.84
Enhancement of salvage of reperfused myocardium by early beta-adrenergic blockade (timolol). J Am Coll Cardiol (1984) 0.82
Beneficial actions of a free radical scavenger in traumatic shock and myocardial ischemia. Circ Shock (1981) 0.82
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74
The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86
Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31
Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92
The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15
The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest (1974) 4.42
TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41
Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33
Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest (1994) 4.28
Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23
A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98
Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82
Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation (1993) 3.68
Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Aortic stenosis. Circulation (1968) 3.49
Sudden cardiac death triggered by an earthquake. N Engl J Med (1996) 3.27
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26
Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24
Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13
Effect of a transient period of ischemia on myocardial cells. II. Fine structure during the first few minutes of reflow. Am J Pathol (1974) 3.09
Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07
Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol (1995) 3.00
Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99
Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98
Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93
A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78
Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72
Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64
Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59
Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47
Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40
Unstable angina: an etiologic approach to management. Circulation (1998) 2.31
The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30
Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29
Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28
Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J (2001) 2.28
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22
Coronary-artery spasm. N Engl J Med (1978) 2.20
Nifedipine therapy for coronary-artery spasm. Experience in 127 patients. N Engl J Med (1980) 2.20
Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol (1986) 2.20
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med (1980) 2.19
Precordial S-T segment elevation mapping: an atraumatic method for assessing alterations in the extent of myocardial ischemic injury. The effects of pharmacologic and hemodynamic interventions. Am J Cardiol (1972) 2.19
Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation (1999) 2.16
Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole. Circulation (1971) 2.15
Velocity of contraction as a determinant of myocardial oxygen consumption. Am J Physiol (1965) 2.11
Effect of glucose-insulin-potassium infusion on myocardial infarction following experimental coronary artery occlusion. Circulation (1972) 2.10
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects. Ann Intern Med (1980) 2.08
Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA (2001) 2.07
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med (1978) 2.03
Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation (2000) 2.01
Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA (1996) 1.99
Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J (2002) 1.98
Modification of myocardial infarction size after coronary occlusion. Ann Intern Med (1973) 1.98
The mechanism of the intraventricular pressure gradient in idiopathic hypertrophic subaortic stenosis. Circulation (1966) 1.97
Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med (1981) 1.97
C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol (1998) 1.96
Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. Circulation (1998) 1.96
Digoxin therapy and mortality after myocardial infarction. Experience in the MILIS Study. N Engl J Med (1986) 1.96
Reflex increase in coronary vascular resistance in patients with ischemic heart disease. N Engl J Med (1976) 1.92
Control of myocardial oxygen consumption: relative influence of contractile state and tension development. J Clin Invest (1968) 1.90
The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation (1987) 1.89
Can medical schools remain the optimal site for the conduct of clinical investigation? Presidential address before the 67th annual meeting of the American Society for Clinical Investigation, Atlantic City, New Jersey, 5 May 1975. J Clin Invest (1975) 1.87
Rapid sequential visualization of the heart and great vessels in man using the wide-field anger scintillation camera. Radioisotope-angiography following the injection of technetium-99m. Circulation (1969) 1.86
Applying the open artery theory: use of predictive survival markers. Eur Heart J (1998) 1.85
Beta-adrenergic receptor blocking drugs. Mechanisms of action and clinical applications. N Engl J Med (1966) 1.83
Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation (1999) 1.83
Cardiovascular control mechanisms in the conscious state. N Engl J Med (1975) 1.82
One-year results of the Thrombolysis in Myocardial Infarction investigation (TIMI) Phase II Trial. Circulation (1992) 1.82
Comparison of clinical outcomes for women and men after acute myocardial infarction. The Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med (1994) 1.78
Contractile state of the left ventricle in man as evaluated from end-systolic pressure-volume relations. Circulation (1977) 1.77
Contractile state of cardiac muscle obtained from cats with experimentally produced ventricular hypertrophy and heart failure. Circ Res (1967) 1.75
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J (2002) 1.73
The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res (2006) 1.70
Thirteenth Bowditch lecture. The determinants of myocardial oxygen consumption. Physiologist (1969) 1.70
Electrocardiographic diagnosis of myocardial infarction in the presence of complete left bundle branch block. Am Heart J (1988) 1.69
New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med (1986) 1.69
Effects of exercise on myocardial force-velocity relations in intact unanesthetized man: relative roles of changes in heart rate, sympathetic activity, and ventricular dimensions. J Clin Invest (1965) 1.67
Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary artery occlusion: which comes first? Circulation (1980) 1.67